ARQTCongressional Stock Trades
Arcutis Biotherapeutics, Inc. Common Stock
Pharmaceutical Preparations
Congressional stock trades in Arcutis Biotherapeutics, Inc. Common Stock (ARQT) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.
Total Trades
1
Politicians Trading
1
Last Traded
Dec 11, 2025
Trading History
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
| Gilbert Ray Cisneros, Jr.D | Jan 12, 2026 | Dec 11, 2025 | Sell | $1,001 - $15,000 | +6.07% |
Price History
About Arcutis Biotherapeutics, Inc. Common Stock
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
1 members of Congress have disclosed 1 trades in Arcutis Biotherapeutics, Inc. Common Stock (ARQT). Most active: Gilbert Ray Cisneros, Jr. (1).
Across all disclosures, members of Congress reported 0 purchases and 1 sales of Arcutis Biotherapeutics, Inc. Common Stock (ARQT). The most recent trade was on Dec 11, 2025.
Gilbert Ray Cisneros, Jr. disclosed selling Arcutis Biotherapeutics, Inc. Common Stock (ARQT) on Dec 11, 2025, valued at $1,001 - $15,000.
From House and Senate periodic transaction reports filed under the STOCK Act. Members of Congress must disclose trades within 45 days, and amounts are reported as ranges, not exact values.